Kenya Depression Therapeutics Market Report 2022 to 2030

Kenya Depression Therapeutics Market Analysis

$ 3999

Kenya's depression therapeutics market is expected to grow from $7 Mn in 2022 to $12 Mn in 2030 with a CAGR of 6.3% for the forecasted year 2022-30. The rising incidence of depression and the increasing disposable incomes of the citizens of Kenya are the major market drivers. The Kenya depression therapeutics market is segmented by drug type, therapies, indication, and end users. Jaskam & Company, Wessex Pharmaceuticals, and Bristol-Myers Squibb are the major players in the Kenya depression therapeutics market.

ID: IN10KEPH034 CATEGORY: Pharmaceuticals GEOGRAPHY: Kenya AUTHOR: Dr. Parul Choudhary

Buy Now

Kenya Depression Therapeutics Market Executive Analysis

Kenya's depression therapeutics market is expected to grow from $7 Mn in 2022 to $12 Mn in 2030 with a CAGR of 6.3% for the forecasted year 2022-30. The Kenyan government has budgeted $1.11 Bn for healthcare services in the fiscal year 2022-23. One of President Uhuru Kenyatta's four major priority items is health care. $0.47 Bn of the $1.11 Bn for health will be spent on initiatives and programs aimed at achieving universal coverage. $53 Mn has been set aside for the purchase of COVID-19 vaccines and associated expenses, with $31 Mn set aside for free maternity health care. $39 Mn will be spent on Managed Equipment Services, while $14 Mn will be used to provide medical coverage for the elderly and seriously disabled members of society.

According to recent WHO estimates, over 300 Mn individuals worldwide are depressed. Kenya, like the rest of the world, has approximately 1.9 Mn depression instances. After South Africa (2.4 Mn cases), the Democratic Republic of the Congo (2.9 Mn cases), Ethiopia (4.5 Mn cases), and Nigeria, it is listed fifth among African countries with the highest number of depression cases. (7.1 Mn cases).

Paroxetine tablets, suspension (liquid), and extended-release (long-acting) tablets are used to treat depression, panic disorder, and social anxiety disorder. Paroxetine tablets and suspension are also used to treat obsessive-compulsive disorder, generalized anxiety disorder, and posttraumatic stress disorder (PTSD). Paxil (paroxetine) was initially authorized as a much-needed and welcomed addition to the antidepressant/antianxiety inventory. Aside from being a serotonin reuptake inhibitor, it also had mild to moderate noradrenergic effects by inhibiting norepinephrine reuptake (NRI or NARI) and could be activating, which often assisted depressed patients with lethargy. Antidepressants act on the serotonin, norepinephrine, and/or dopamine chemical receptors in the brain. Tricyclic Antidepressants (TCAs) inhibit norepinephrine reuptake pumps, as well as serotonin reuptake, pumps to different degrees. Their impacts on acetylcholine, histamine, and adrenergic receptors frequently result in undesirable side effects. (e.g., weight gain, sedation, constipation, dry mouth, orthostatic hypotension, reflex tachycardia). Secondary amine TCAs (e.g., nortriptyline [Pamelor], desipramine [Norpramin]) have fewer adverse effects than tertiary amines (e.g., imipramine [Tofranil], amitriptyline).

Kenya Depression Therapeutics Market Analysis

Market Dynamics

Market Growth Drivers

Depression is becoming more prevalent. In recent years, there has been an increase in understanding and acceptance of mental health topics in Kenya. Depression therapeutics are in high demand as more people seek treatment for mental health problems. Kenya has been investing in its healthcare infrastructure, which includes hospitals, clinics, and medical personnel. This outlay is anticipated to improve access to mental health services, leading to a rise in demand for depression treatment. As the economy matures, many Kenyans' disposable income increases. As a result, there is a higher demand for healthcare services such as mental health services and depression treatment, which is driving the Kenya depression therapeutics market expansion.

Market Restraints

Despite ongoing funds for healthcare infrastructure, Kenya continues to face resource limitations, such as a lack of qualified mental health workers and inadequate access to mental health services in some parts. This could limit the progress of the market for depression therapeutics. Depression therapeutics can be expensive, which may limit their availability to many Kenyans who cannot afford the treatment. This could be a major impediment to market development. In Kenya, healthcare insurance coverage is limited, and many policies do not cover mental health treatments. This may limit the Kenya depression therapeutics market growth because many people may not have the monetary means to pay for treatment out of pocket.

Competitive Landscape

Key Players

Regal Pharmaceuticals (KEN)
Mac's Pharmaceuticals (KEN)
Sunpar Pharmaceuticals (KEN)
Jaskam & Company (KEN)
Wessex Pharmaceuticals (KEN)
Bristol-Myers Squibb
Cipla
Eli Lily
GlaxoSmithKline
Johnson & Johnson
Merck
Zydus Lifesciences

Healthcare Policies and Regulatory Landscape

Prior to 2015, the National Hospital Insurance Fund (NHIF) only provided rebates for inpatient services to its users. This arrangement lacked breadth for some critical medical services needed by its members, namely surgical care and specialized laboratory investigations. This meant that members were still paying out of pocket to receive advanced therapy. The NHIF, Kenya's national health insurance plan, covers some mental health services such as consultations, counselling, and medication. However, coverage is limited and may not be enough to cover the cost of more intensive depression therapy, such as inpatient care. Kenya currently has no reimbursement policies in effect for mental health care. This can make it difficult for mental health providers to obtain payment for their services, potentially resulting in limited access to care.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Depression Therapeutics Segmentation

By Drug Type (Revenue, USD Billion):

Antidepressants
Anxiolytics
Anticonvulsants
Noradrenergic Agents
Atypical Antipsychotics

By Therapies (Revenue, USD Billion):

Electroconvulsive Therapy (ECT)
Cognitive Behaviour Therapy (CBT)
Psychotherapy
Deep Brain Stimulation
Transcranial Magnetic Stimulation (TMS)
Cranial electrotherapy stimulation (CES)

By Indication (Revenue, USD Billion):

Major Depressive Disorder (MDD)
Bipolar Disorder
Dysthymic Disorder
Postpartum Depression
Seasonal Affective Disorder (SAD)
Premenstrual Dysphoric Disorder (PMDD)
Others

By End Users (Revenue, USD Billion):

NGOs
Asylums
Hospitals
Mental Healthcare Centers

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.

To request a free sample copy of this report, please complete the form below.

We value your inquiry and offer free customization with every report to fulfil your exact research needs.

Yes, I have read the privacy policy

Jaskam & Company, Wessex Pharmaceuticals, and Bristol-Myers Squibb are the major players in the Kenya depression therapeutics market.

The Kenya depression therapeutics market is expected to grow from $7 Mn in 2022 to $12 Mn in 2030 with a CAGR of 6.3% for the forecasted year 2022-2030.

The Kenya depression therapeutics market is segmented by drug type, therapies, indication, and by end users.